On this page
Surital
Thiamylal Sodium
Overview
Source: Animal Drugs @ FDAAdverse event reports
Source: openFDA VeDDRAAttributed by active ingredient “THIAMYLAL”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.
Reported reactions
Source: openFDA VeDDRAClinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.
| Reaction (VeDDRA term) | Reports | Relative frequency |
|---|---|---|
| Apnoea | 44 | |
| Death | 37 | |
| Cardiac arrest | 23 | |
| INEFFECTIVE, ANESTHESIA | 20 | |
| Recovery prolonged | 19 | |
| Prolonged anaesthesia | 9 | |
| Hyperexcitation | 3 | |
| Arrhythmia | 3 | |
| Bradypnoea | 3 | |
| Hypersalivation | 2 | |
| Dyspnoea | 2 | |
| Cyanosis | 2 | |
| Unclassifiable adverse event | 2 | |
| Ataxia | 1 | |
| Vomiting | 1 | |
| Hypothermia | 1 | |
| Haemoptysis | 1 | |
| PR-LUNG(S), LESION(S) | 1 | |
| Tachycardia | 1 | |
| Convulsion | 1 |
Species affected
Source: openFDA VeDDRARegulatory context
New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.
Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.
Sources for this page
| Animal Drugs @ FDA | FDA CVM | Applications, sponsor, status, withdrawal |
| Animal & Veterinary Events | FDA CVM | VeDDRA adverse event aggregates by active ingredient |